Title
Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban
A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation
Phase
Phase 4Lead Sponsor
Guangdong Provincial People's HospitalStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Atrial Fibrillation StrokeIntervention/Treatment
rivaroxaban ...Study Participants
200This is a prospective, multi-center, randomized, pilot study comparing the WATCHMAN left atrial appendage occlusion device with Rivaroxaban therapy in patients with non-valvular atrial fibrillation.
Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.
Subjects assigned to receive the Rivaroxaban therapy.
Inclusion Criteria: Paroxysmal, persistent or permanent non-valvular atrial fibrillation Eligible for LAAO and long-term rivaroxaban therapy Calculated CHA2DS2-VASc score of 2 or greater. Exclusion Criteria: Contraindicated/allergic to aspirin, clopidogrel and novel oral anticoagulants. Indicated for clopidogrel therapy or has taken clopidogrel within 7 days prior to enrollment. History of atrial septal repair or has an atrial septal defect/patent foramen ovale device. History of valvular heart disease. Implanted mechanical valve prosthesis. New York Heart Association Class IV congestive heart failure or left ventricular ejection fraction less than 30%. Patient has left atrial/left atrial appendage thrombus screened by echocardiography Platelet<100*109/L or hemoglobin<100g/L Expected lifespan less than 1 years